iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 47.3% in July

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totaling 57,108 shares, a decrease of 47.3% from the June 30th total of 108,461 shares. Based on an average trading volume of 69,290 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.0% of the company’s stock are short sold.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

An institutional investor recently raised its position in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. grew its position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) by 8.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,473 shares of the company’s stock after buying an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 as of its most recent filing with the Securities & Exchange Commission.

iShares Genomics Immunology and Healthcare ETF Trading Down 0.9%

Shares of IDNA traded down $0.30 during trading hours on Wednesday, reaching $32.15. 29,473 shares of the stock traded hands, compared to its average volume of 43,384. The stock has a fifty day simple moving average of $31.52 and a 200 day simple moving average of $30.15. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $20.93 and a 52 week high of $34.97. The company has a market cap of $189.69 million, a price-to-earnings ratio of 14.76 and a beta of 0.92.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.